Table 1 Baseline Demographic and Clinical Characteristics
From: Robot-assisted functional minimally invasive radical resection of esophageal cancer
Parameter | Before matching | P Value | After matching | P Value |
|---|---|---|---|---|
FMIE | n = 66 | n = 40 | ||
RAFMIE | n = 44 | n = 40 | ||
Age (years) | 0.081 | 0.982 | ||
FMIE | 69.61 ± 6.55 | 67.97 ± 6.08 | ||
RAFMIE | 67.50 ± 4.00 | 67.95 ± 3.82 | ||
Gender [n (%)] | Male | 0.167 | Male | 0.796 |
FMIE | 48 (72.73%) | 31 (77.50%) | ||
RAFMIE | 34 (77.27%) | 30 (75.00%) | ||
BMI (kg/m2) | 0.645 | 0.736 | ||
FMIE | 26.11 ± 0.65 | 26.10 ± 0.47 | ||
RAFMIE | 26.05 ± 0.67 | 26.10 ± 0.53 | ||
ASA score [n (%)] | 0.005 | 1.000 | ||
FMIE | ||||
ASA1 | 0 (0%) | 0(0%) | ||
ASA2 | 53 (80.3%) | 31 (77.5%) | ||
ASA3 | 13 (19.7%) | 9 (22.5%) | ||
ASA4 | 0 (0%) | 0 (0%) | ||
RAFMIE | ||||
ASA1 | 0 (0%) | 0 (0%) | ||
ASA2 | 35 (79.5%%) | 31 (77.5%) | ||
ASA3 | 9 (20.5%) | 9 (22.5%) | ||
ASA4 | 0 (0%) | 0 (0%) | ||
Smoking [n (%)] | Yes | 0.627 | Yes | 0.812 |
FMIE | 43 (63.64) | 27 (67.50%) | ||
RAFMIE | 31 (68.18%) | 28 (70.00%) | ||
Neoadjuvanttherapy [n (%)] | Yes | 0.809 | Yes | 0.649 |
FMIE | 23 (34.85%) | 16 (40.00%) | ||
RAFMIE | 15 (34.09%) | 14 (35.00%) | ||
Comorbidity [n (%)] | 0.780 | 1.000 | ||
FMIE | 15 (22.73%) | 9 (22.50%) | ||
hypertension | 6 | 4 | ||
coronary heart disease | 7 | 4 | ||
diabetes mellitus | 1 | 0 | ||
others | 1 | 1 | ||
RAFMIE | 9 (20.45%) | 9 (22.50%) | ||
hypertension | 4 | 4 | ||
coronary heart disease | 4 | 3 | ||
diabetes mellitus | 1 | 1 | ||
others | 0 | 1 | ||
Length of tumor(cm) | 0.389 | 0.455 | ||
FMIE | 5.01 ± 2.01 | 4.90 ± 1.95 | ||
RAFMIE | 4.66 ± 2.25 | 4.55 ± 2.22 | ||
Tumor location [n (%)] | 0.533 | 0.228 | ||
FMIE | ||||
upper | 2 (3.03%) | 2 (5.00%) | ||
middle | 35 (53.03%) | 20 (50.00%) | ||
lower | 29 (43.94%) | 18 (45.00%) | ||
RAFMIE | 40 | |||
upper | 2 (4.55%) | 1 (4.55%) | ||
middle | 25 (56.82%) | 24 (56.82%) | ||
Lower | 17 (38.64%) | 15 (38.64%) | ||
Pathological pattern[n (%)] | 0.535 | 0.302 | ||
FMIE | ||||
squamous carcinoma | 62 (93.94) | 39 (97.50%) | ||
adenocarcinoma | 3 (4.55%) | 1 (2.50%) | ||
mucoepidermoid | 1 (1.52%) | 0 (0%) | ||
high-gradeintraepithelial | 0 (0%) | 0 (0%) | ||
RAFMIE | ||||
squamous carcinoma | 40 (90.91%) | 37 (92.5%) | ||
adenocarcinoma | 3 (6.82%) | 2 (5.00%) | ||
mucoepidermoid | 0(0%) | 0 (0%) | ||
high-gradeintraepithelial | 1 (2.27%) | 1 (2.50%) | ||
cT-status | 0.791 | 0.631 | ||
FMIE | ||||
cT1 | 10 (15.15%) | 8 (20.00%) | ||
cT2 | 26 (39.40%) | 12 (30.00%) | ||
cT3 | 30 (45.45%) | 20 (50.00%) | ||
cT4 | 0 (0%) | 0 (0%) | ||
RAFMIE | ||||
cT1 | 12 (27.27%) | 11 (27.50%) | ||
cT2 | 10 (22.73%) | 10 (25.00%) | ||
cT3 | 22 (50.00%) | 19 (47.50%) | ||
cT4 | 0 (0%) | 0 (0%) | ||
cN-status | 0.916 | 0.907 | ||
FMIE | ||||
cN0 | 26 (39.39%) | 14 (35.00%) | ||
cN1 | 31 (46.97%) | 24 (60.00%) | ||
cN2 | 9 (13.64%) | 2 (5.00%) | ||
cN3 | 0 | 0 | ||
RAFMIE | ||||
cN0 | 20 (45.45%) | 18 (45.00%) | ||
cN1 | 15 (34.09%) | 15 (37.50%) | ||
cN2 | 9 (20.45%) | 7 (17.50%) | ||
cN3 | 0 | 0 | ||
Pathologic stage[n (%)] | 0.892 | 0.837 | ||
FMIE | ||||
I | 11 (16.67%) | 8 (20.00%) | ||
II | 25 (37.88%) | 12 (30.00%) | ||
III | 28 (42.42%) | 19 (47.50%) | ||
IV | 2 (3.03%) | 1 (2.50%) | ||
RAFMIE | ||||
I | 12 (27.27%) | 12 (30.00%) | ||
II | 10 (22.73%) | 8 (20.00%) | ||
III | 19 (43.18%) | 17 (42.50%) | ||
IV | 3 (6.82%) | 3 (7.50%) | ||